JP7768769B2 - リゾチームを含む広域スペクトル抗菌製剤およびその使用方法 - Google Patents

リゾチームを含む広域スペクトル抗菌製剤およびその使用方法

Info

Publication number
JP7768769B2
JP7768769B2 JP2021571513A JP2021571513A JP7768769B2 JP 7768769 B2 JP7768769 B2 JP 7768769B2 JP 2021571513 A JP2021571513 A JP 2021571513A JP 2021571513 A JP2021571513 A JP 2021571513A JP 7768769 B2 JP7768769 B2 JP 7768769B2
Authority
JP
Japan
Prior art keywords
formulation
lysozyme
weight
pharmaceutical formulation
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534776A (ja
JPWO2020240472A5 (https=
JP2022534776A5 (https=
Inventor
アイバル－バティスタ，ディオヘネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aybar Ecotechnologies Corp
Original Assignee
Aybar Ecotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aybar Ecotechnologies Corp filed Critical Aybar Ecotechnologies Corp
Publication of JP2022534776A publication Critical patent/JP2022534776A/ja
Publication of JPWO2020240472A5 publication Critical patent/JPWO2020240472A5/ja
Publication of JP2022534776A5 publication Critical patent/JP2022534776A5/ja
Priority to JP2024215483A priority Critical patent/JP2025038034A/ja
Priority to JP2025183379A priority patent/JP2026021451A/ja
Application granted granted Critical
Publication of JP7768769B2 publication Critical patent/JP7768769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021571513A 2019-05-28 2020-05-28 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法 Active JP7768769B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024215483A JP2025038034A (ja) 2019-05-28 2024-12-10 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
JP2025183379A JP2026021451A (ja) 2019-05-28 2025-10-30 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853215P 2019-05-28 2019-05-28
US62/853,215 2019-05-28
PCT/IB2020/055083 WO2020240472A1 (en) 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024215483A Division JP2025038034A (ja) 2019-05-28 2024-12-10 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
JP2025183379A Division JP2026021451A (ja) 2019-05-28 2025-10-30 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022534776A JP2022534776A (ja) 2022-08-03
JPWO2020240472A5 JPWO2020240472A5 (https=) 2023-06-14
JP2022534776A5 JP2022534776A5 (https=) 2023-06-14
JP7768769B2 true JP7768769B2 (ja) 2025-11-12

Family

ID=73551002

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021571513A Active JP7768769B2 (ja) 2019-05-28 2020-05-28 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
JP2024215483A Pending JP2025038034A (ja) 2019-05-28 2024-12-10 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
JP2025183379A Pending JP2026021451A (ja) 2019-05-28 2025-10-30 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024215483A Pending JP2025038034A (ja) 2019-05-28 2024-12-10 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
JP2025183379A Pending JP2026021451A (ja) 2019-05-28 2025-10-30 リゾチームを含む広域スペクトル抗菌製剤およびその使用方法

Country Status (12)

Country Link
US (3) US20200376094A1 (https=)
EP (1) EP3976093A4 (https=)
JP (3) JP7768769B2 (https=)
CN (1) CN114126643A (https=)
AR (1) AR119031A1 (https=)
BR (1) BR112021024001A2 (https=)
CA (1) CA3145530A1 (https=)
CO (1) CO2021017958A2 (https=)
IL (1) IL288531A (https=)
MX (1) MX2021014634A (https=)
TW (1) TW202110474A (https=)
WO (1) WO2020240472A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3928785B1 (en) * 2020-04-27 2024-07-31 Guangzhou Century Clinical Research Co., Ltd Medicament and food for use in preventing or treating novel coronavirus pneumonia covid-19
EP4144363A4 (en) * 2020-04-27 2024-05-29 Guangzhou Century Clinical Research Co., Ltd Drug, food and application of anti-coronavirus infection
WO2023133412A2 (en) * 2022-01-05 2023-07-13 Prophase Labs, Inc. Compositions having synergistic anti-viral action and methods for treating coronavirus
CN114503981A (zh) * 2022-01-07 2022-05-17 上海膜益信息科技有限公司 一种不分层防霉液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
CN1557485A (zh) * 2004-01-30 2004-12-29 大连帝恩生物工程有限公司 基因重组人溶菌酶在消除病原微生物感染炎症上的应用
CA2561876C (en) * 2004-04-08 2013-01-08 Kenneth Vincent Mason Antimicrobial compositions and methods for their use
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
WO2009051838A1 (en) * 2007-10-19 2009-04-23 Becton Dickinson And Company Methods and compositions for the detection of beta-lactamases
EP2349209A2 (en) * 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
UA48016U (ru) * 2010-01-25 2010-02-25 Илона Васильевна Ковач Способ профилактики кариеса зубов у детей 3-6 лет
UA68612U (ru) * 2012-02-07 2012-03-26 Дмитрий Викторович Дудар Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией
CA2905788C (en) * 2013-03-12 2022-08-16 Emily A. Stein Dental composition comprising chelator and base
CN110352237B (zh) * 2017-02-28 2023-01-10 精密生物集团有限公司 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌
EP3655020A4 (en) * 2017-07-17 2021-04-07 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Antibacterial methods and related kits
CN107899006A (zh) * 2017-11-28 2018-04-13 四川清舒乐科技有限公司 冲洗鼻腔的药物组合物及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY，1987年，Vol.53, No.9, pp.2165-2170
Poultry Science，2009年，Vol.88, pp.406-414
ウクライナ国実用新案第４８０１６号明細書（ＵＡ ４８０１６ Ｕ）
ウクライナ国実用新案第６８６１２号明細書（ＵＡ ６８６１２ Ｕ）

Also Published As

Publication number Publication date
CA3145530A1 (en) 2020-12-03
CN114126643A (zh) 2022-03-01
CO2021017958A2 (es) 2022-01-17
JP2022534776A (ja) 2022-08-03
AR119031A1 (es) 2021-11-17
IL288531A (en) 2022-01-01
WO2020240472A1 (en) 2020-12-03
US20240066105A1 (en) 2024-02-29
US20220362354A1 (en) 2022-11-17
US20200376094A1 (en) 2020-12-03
EP3976093A1 (en) 2022-04-06
EP3976093A4 (en) 2023-07-05
TW202110474A (zh) 2021-03-16
BR112021024001A2 (pt) 2022-01-25
JP2026021451A (ja) 2026-02-10
JP2025038034A (ja) 2025-03-18
MX2021014634A (es) 2022-07-04

Similar Documents

Publication Publication Date Title
JP7768769B2 (ja) リゾチームを含む広域スペクトル抗菌製剤およびその使用方法
BR112012018170B1 (pt) Agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
US20240325332A1 (en) Bactericidal and virucidal pharmaceutical composition
BR112018000592B1 (pt) Composição de desbloqueio de nariz congestionado tendo atividade antiviral
US20200352986A1 (en) Methods and compositions for alleviating respiratory dysfunction
HUP0002125A2 (hu) Tökéletesített retard hatású mikróbaellenes szerek
Wang Roles of oral bacteria in cardiovascular diseases—from molecular mechanisms to clinical cases: treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin
US20160279043A1 (en) Combinations of n-acetyl cysteine derivatives and cranberry polyphenols in compositions and methods for preventing and treating periodontal diseases and peri-implatitis
RU2762506C1 (ru) Средство для аппликации полости рта и носа и способ его применения в составе комплексной терапии инфекционно-воспалительных заболеваний носовой и ротовой полости
Meyers et al. Bacteriological, pharmacological, and clinical studies of carbenicillin
US20060142254A1 (en) Antipyretic preparation containing xylitol
RU2053765C1 (ru) Лекарственное средство для профилактики простудных заболеваний у детей
JP2004529095A (ja) 抗菌性ｉｂ−３６７ペプチドの経口投与による人工呼吸器関連性肺炎の予防法
Tjernström et al. Ototoxicity of netilmicin
RU2810419C1 (ru) Способ лечения хронического пародонтита
Jones Intranasal xylitol, recurrent otitis media, and asthma: Report of three cases
RU2837356C1 (ru) Жидкая фармацевтическая композиция на основе комбинации бензидамина, октенидина и феноксиэтанола для профилактики и лечения инфекционных и воспалительных заболеваний лор-органов
JPH0327313A (ja) 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物
Wilson et al. Comparison of the Effectiveness of Oral and Intravenous Antibiotics for the Treatment of Acute Sinusitis in Children at Skopje Hospital, Macedonia
WO2021204861A1 (en) Compositions for use in the inhibition of coronavirus replication
ÖZKAN REPAIR (LSTR)
JP2024507417A (ja) イヌパルボウイルス感染を治療するための組成物および方法
EP2192912B1 (en) Essential oil of kunzea ambigua and methods of use
US20120107419A1 (en) Oral rinse formulation and method of use
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7768769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150